| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Bret, C Jolivel, M C Bret, S Veylit, C Martin, P Garci. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809242. |
although the acquisition cost of clozapine is high, cost effectiveness estimates in patients with treatment resistant schizophrenia suggest that the clinical benefits (improved psychopathology, social functioning and quality of life) of this drug may confer medium to long term economic benefits, primarily by reducing the need for psychiatric hospital service. |
1999-01-05 |
2023-08-12 |
Not clear |
| W J Naja, J P Reneric, M P Bouvar. [Atypical neuroleptics in the child and adolescent]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809243. |
the fda approval for clozapine in 1990 under several hematologic surveillance conditions has reactualized the debate on the use of atypical neuroleptics for adults with schizophrenia. |
1999-01-05 |
2023-08-12 |
human |
| W J Naja, J P Reneric, M P Bouvar. [Atypical neuroleptics in the child and adolescent]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809243. |
since 1992 several studies concerning children and adolescents show the efficiency and the tolerance of the clozapine and risperidone in various disorders, especially in very early onset schizophrenia (veos). |
1999-01-05 |
2023-08-12 |
human |
| D C Henderson, R A Nasrallah, D C Gof. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. The Journal of clinical psychiatry. vol 59. issue 11. 1999-01-05. PMID:9862604. |
switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. |
1999-01-05 |
2023-08-12 |
Not clear |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious in reducing the psychotic symptomatology of schizophrenia as well as inducing less extrapyramidal side-effects. |
1998-12-30 |
2023-08-12 |
human |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious and safe in the treatment of schizophrenia. |
1998-12-30 |
2023-08-12 |
human |
| R Rosenheck, W Lawson, J Crayton, J Cramer, W Xu, J Thomas, M Stolar, D Charne. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biological psychiatry. vol 44. issue 6. 1998-12-28. PMID:9777179. |
veterans affairs cooperative study group on clozapine in refractory schizophrenia. |
1998-12-28 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
we tested the hypothesis that the most severe schizophrenia requiring treatment with clozapine would particularly show these effects. |
1998-11-06 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
by the end of 1994, seventeen (22%) of a total 76 dsm-iii-r schizophrenia patients, had received clozapine treatment. |
1998-11-06 |
2023-08-12 |
Not clear |
| T Mäkikyrö, E Leinonen, H Koponen, M R Järvelin, H Hakko, O Saarnisaari, M Isohann. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics. Journal of psychiatric research. vol 32. issue 2. 1998-11-06. PMID:9694006. |
there was no evidence that severe schizophrenia requiring treatment with clozapine was associated with impaired intrauterine or post-natal development. |
1998-11-06 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, G Facciolà, M Fabrazzo, P Monteleone, M Maj, E Perucca, A P Caput. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690983. |
effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| D L Roe, M E Bardgett, C A Csernansky, J G Csernansk. Induction of Fos protein by antipsychotic drugs in rat brain following kainic acid-induced limbic-cortical neuronal loss. Psychopharmacology. vol 138. issue 2. 1998-10-26. PMID:9718284. |
since limbic-cortical pathology has been implicated in the negative symptoms of schizophrenia, the enhanced effect of clozapine on limbic-cortical expression of c-fos in ka-lesioned rats may be relevant to understanding clozapine's unusual therapeutic actions in patients with schizophrenia. |
1998-10-26 |
2023-08-12 |
rat |
| W Koren, E Koren, N Nacasch, M Ehrenfeld, H Gu. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clinical neuropharmacology. vol 21. issue 4. 1998-10-22. PMID:9704170. |
a 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. |
1998-10-22 |
2023-08-12 |
Not clear |
| W H Reid, M Mason, T Hoga. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric services (Washington, D.C.). vol 49. issue 8. 1998-10-14. PMID:9712207. |
suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. |
1998-10-14 |
2023-08-12 |
Not clear |
| W H Reid, M Mason, T Hoga. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric services (Washington, D.C.). vol 49. issue 8. 1998-10-14. PMID:9712207. |
this study examined annual suicide rates over a two-year period (1993-1995) among more than 30,000 patients with schizophrenia and schizoaffective disorder who received services from the texas department of mental health and mental retardation and suicide rates over a six-year period (1991-1996) among a subgroup of patients treated with clozapine. |
1998-10-14 |
2023-08-12 |
Not clear |
| R A Dickson, L Hog. Pregnancy of a patient treated with clozapine. Psychiatric services (Washington, D.C.). vol 49. issue 8. 1998-10-14. PMID:9712217. |
the authors describe the case of a patient with treatment-resistant schizophrenia who became pregnant after switching from conventional neuroleptic medications to clozapine, an atypical antipsychotic medication that does not cause hyperprolactinemia. |
1998-10-14 |
2023-08-12 |
Not clear |
| M J Millan, R Schreiber, A Dekeyne, J M Rivet, K Bervoets, M Mavridis, C Sebban, S Maurel-Remy, A Newman-Tancredi, M Spedding, O Muller, G Lavielle, M Brocc. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. The Journal of pharmacology and experimental therapeutics. vol 286. issue 3. 1998-10-08. PMID:9732399. |
s 16924 antagonized locomotion provoked by dizocilpine and cocaine, reduced conditioned avoidance responses and blocked climbing elicited by apomorphine, models predictive of control of the positive symptoms of schizophrenia: its median inhibitory dose (id)50 was 0.96 mg/kg, s.c. vs. 1.91 for clozapine and 0.05 for haloperidol. |
1998-10-08 |
2023-08-12 |
human |
| J Thompson, K N Chengappa, C B Good, R W Baker, R P Kiewe, J Bezner, N R Schoole. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. International clinical psychopharmacology. vol 13. issue 2. 1998-10-01. PMID:9669191. |
this report describes a 48-year-old caucasian male with schizophrenia who developed hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria early in clozapine treatment which resolved on drug discontinuation. |
1998-10-01 |
2023-08-12 |
Not clear |
| J C Connelly, J Fullic. Experience with clozapine in a community mental health care setting. Southern medical journal. vol 91. issue 9. 1998-10-01. PMID:9743054. |
clozapine has been heralded as the first major breakthrough in antipsychotic drug therapy for treatment-resistant schizophrenia in 40 years. |
1998-10-01 |
2023-08-12 |
Not clear |
| K E Ferslew, A N Hagardorn, G C Harlan, W F McCormic. A fatal drug interaction between clozapine and fluoxetine. Journal of forensic sciences. vol 43. issue 5. 1998-09-24. PMID:9729831. |
clozapine is a tricyclic dibenzodiazepine derivative used as an "atypical antipsychotic" in the treatment of severe paranoid schizophrenia. |
1998-09-24 |
2023-08-12 |
Not clear |